欧盟HMA药品数据库（European Union HMA Authorisation of Medicines DataBase）

MR编号	DE/H/6801/001
药品名称	Cabazitaxel Glenmark 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung
活性成分	Cabazitaxel 20.0 mg/ml
剂型	Concentrate for solution for infusion
上市许可持有人	Glenmark Arzneimittel GmbH Industriestr. 31 82194 Gröbenzell Germany
参考成员国 - 产品名称	Germany (DE) Cabazitaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung
互认成员国 - 产品名称	Italy (IT) Denmark (DK) Finland (FI) Norway (NO) Sweden (SE)
许可日期	2020/11/10
最近更新日期	2024/04/25
药物ATC编码	L01CD04 cabazitaxel
申请类型	TypeLevel1：Abridged TypeLevel2：Initial Application TypeLevel3：Other Generic application Art 10.3 Dir 2001/83/EC TypeLevel4：Chemical Substance TypeLevel5：Prescription Only
附件文件下载	Final SPC \| final_common_spc_6801_005Date of last change:2024/01/09 PAR \| Cabazitaxel_AqVida _ final PARDate of last change:2022/06/02 Final Product Information \| common-final-pl-6801-V002Date of last change:2021/12/15 Final Product Information \| common-final-spc-6801-V002Date of last change:2021/12/15 Final Labelling \| 1-3-1-labip-common-Cabazitaxel-AqVidaDate of last change:2020/11/14 Final Labelling \| 1-3-1-labip-common-Cabazitaxel-AqVidaDate of last change:2020/11/14 Final Labelling \| 1-3-1-labop-common-Cabazitaxel-AqVida_2Date of last change:2020/11/14 Final Labelling \| 1-3-1-labop-common-Cabazitaxel-AqVidaDate of last change:2020/11/14
市场状态	Positive